Sarepta Therapeutics Inc. (srpt 1.25 09/15/27)
13F holders, Q1 2026 (March 31)6holders +2
4new positions
2sold out
$0.92avg. 13F price*
At the end of Q1 2026, 6 institutions reported holding Sarepta Therapeutics Inc. (srpt 1.25 09/15/27) in their 13F filings, up 2 from Q4 2025. 4 opened new positions and 2 sold out. The largest holders were BNP PARIBAS ASSET MANAGEMENT Holding S.A. ($3.2M), Financial Consulate, Inc. ($920K) and HB Wealth Management, LLC ($511K).
- Company
- Sarepta Therapeutics Inc. (srpt 1.25 09/15/27)
- CUSIP
- 803607AD2
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $1.5M |
| Exits | 2 | $3.5M |
All 13F filers, Q4 2025 → Q1 2026: 1,594,000 shares bought and 3,953,000 shares sold, net −2,359,000 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 6 holders
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 0.00% | No change | 3,500,000 | $3.2M |
| Financial Consulate, Inc. | 0.11% | New | 999,000 | $920K |
| HB Wealth Management, LLC | 0.00% | New | 555,000 | $511K |
| Wealthspire Advisors, LLC | 0.00% | New | 27,000 | $25K |
| Cambridge Investment Research Advisors, Inc. | 0.00% | New | 13,000 | $12K |
| Rothschild Investment LLC | 0.00% | No change | 1,000 | $919 |
"% of holder's portfolio" is SAREPTA THERAPEUTICS INC (SRPT 1.25 09/15/27)'s weight in each manager's 13F, not the share of Sarepta Therapeutics Inc. (srpt 1.25 09/15/27) the manager owns.